Endpoints News· @endpts · X·· 22 天前精选AI 评分62
AI 导读
BioNTech与DualityBio正在评估其HER2 ADC在乳腺癌III期试验后的下一步,该结果被描述为“温和”的胜利。报道未披露具体疗效数据,仅指向Endpoints News的详细报道链接。
推荐理由
BioNTech与DualityBio的HER2 ADC在乳腺癌III期取得被描述为温和的胜利,双方正评估后续路径。
正文
BioNTech and DualityBio are weighing next steps for their HER2 ADC after a “modest” Phase 3 win in breast cancer. https://endpoints.news/biontech-dualitybio-ponder-next-steps-for-her2-adc-after-modest-breast-cancer-results/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial
来源:Endpoints News · x.com